A Systematic Review on Cost-effectiveness Analyses of Therapeutic Drug Monitoring for Patients with Inflammatory Bowel Disease: From Immunosuppressive to Anti-TNF Therapy

Inflammatory Bowel Disease

Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease

Inflamm Bowel Dis.

Lyles JL, Mulgund AA, Bauman LE, Su W, Fei L, Chona DL, Sharma P, Etter RK, Hellmann J, Denson LA, Minar P, Dykes DM, Rosen MJ

doi: 10.1093/ibd/izaa102.

Inflammatory Bowel Disease

The Effect of Initiation of Anti-TNF Therapy on the Subsequent Direct Health Care Costs of Inflammatory Bowel Disease

Inflamm Bowel Dis.

Targownik LE, Benchimol EI, Witt J, Bernstein CN, Singh H, Lix L, Tennakoon A, Zubieta AA, Coward S, Jones J, Kuenzig E, Murthy SK, Nguyen GC, Peña-Sánchez JN, Kaplan G

doi: 10.1093/ibd/izz063.

Inflammatory Bowel Disease

Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients with Inflammatory Bowel Diseases: a Systematic Review and Meta-analysis

Clin Gastroenterol Hepatol.

Singh S, Facciorusso A, Dulai PS, Jairath V, Sandborn WJ

doi: 10.1016/j.cgh.2019.02.044.

RECOMMENDED

Inflammatory Bowel Disease

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases

Clin Gastroenterol Hepatol.

Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Casteele NV, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, Jones J, Kaplan GG, Sparrow MP, Velayos FS, Ullman T, Siegel CA

doi: 10.1016/j.cgh.

RECOMMENDED

Inflammatory Bowel Disease

Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus

Digestion.

Greuter T, Maillard MH, Juillerat P, Michetti P, Seibold F, Mottet C, Zahnd N, Sauter B, Schoepfer AM, Rogler G, Vavricka SR, on behalf of the Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology.

doi: 10.1159/000501930.

Inflammatory Bowel Disease

Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry

Inflamm Bowel Dis.

Casanova MJ, Chaparro M, Mínguez M, Ricart E, Taxonera C, García-López S, Guardiola J, López-San Román A, Iglesias E, Beltrán B, Sicilia B, Vera MI, Hinojosa J, Riestra S, Domènech E, Calvet X, Pérez-Calle JL, Martín-Arranz MD, Aldeguer X, Rivero M, Monfort D, Barrio J, Esteve M, Márquez L, Lorente R, García-Planella E, de Castro L, Bermejo F, Merino O, Rodríguez-Pérez A, Martínez-Montiel P, Van Domselaar M, Alcaín G, Domínguez-Cajal M, Muñoz C, Gomollón F, Fernández-Salazar L, García-Sepulcre MF, Rodríguez-Lago I, Gutiérrez A, Argüelles-Arias F, Rodriguez C, Rodríguez GE, Bujanda L, Llaó J, Varela P, Ramos L, Huguet JM, Almela P, Romero P, Navarro-Llavat M, Abad Á, Ramírez-de la Piscina P, Lucendo AJ, Sesé E, Madrigal RE, Charro M, García-Herola A, Pajares R, Khorrami S, Gisbert JP

doi: 10.1093/ibd/izz192.

Inflammatory Bowel Disease

Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort

Scand J Gastroenterol.

Buer LCT, Moum BA, Cvancarova M, Warren DJ, Bolstad N, Medhus AW, Høivik ML

doi: 10.1080/00365521.

Inflammatory Bowel Disease

Increased prevalence of anti-TNF therapy in paediatric inflammatory bowel disease is associated with a decline in surgical resections during childhood

Aliment Pharmacol Ther.

Ashton JJ, Borca F, Mossotto E, Coelho T, Batra A, Afzal NA, Phan HTT, Stanton M, Ennis S, Beattie RM

doi: 10.1111/apt.15094.

Inflammatory Bowel Disease

Disease-Associated Costs in Children With Inflammatory Bowel Disease: A Systematic Review

Inflamm Bowel Dis.

El-Matary W, Kuenzig ME, Singh H, Okoli G, Moghareh M, Kumar H, Lê ML, Benchimol EI

doi: 10.1093/ibd/izz120.

Related content

Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease

The Effect of Initiation of Anti-TNF Therapy on the Subsequent Direct Health Care Costs of Inflammatory Bowel Disease

Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients with Inflammatory Bowel Diseases: a Systematic Review and Meta-analysis

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases

Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus

Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry

Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort

Increased prevalence of anti-TNF therapy in paediatric inflammatory bowel disease is associated with a decline in surgical resections during childhood

Disease-Associated Costs in Children With Inflammatory Bowel Disease: A Systematic Review